---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-058379"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T12:22:29.548848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated

## Summary
- COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
- Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.
- Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.
- Novavax continues to pursue partnering opportunities to advance further development of these programs.

## SEC filing metadata
- accession: 0001104659-25-058379
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/0001104659-25-058379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925058379/tm2517661d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-058379
- JSON: https://secwatch.observer/filing/0001104659-25-058379.json
- Plain text: https://secwatch.observer/filing/0001104659-25-058379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.